Medtronic announced fourth-quarter financial results for its 2024 fiscal year on Thursday. Here are three things to know:

Ending the year strong

Strong performance across our businesses continued to fuel mid-single-digit revenue growth during the fourth quarter. Notable growth drivers included products in our Cranial & Spinal Technologies business, the Micra™ leadless pacemaker franchise, and pulsed-field ablation technologies.

It’s just the beginning

Many innovative Medtronic therapies are just beginning to reach patients. These recently launched technologies – which treat conditions ranging from high blood pressure to atrial fibrillation – put us in a strong position to grow.

Looking ahead to fiscal year 2025

For our next fiscal year, we expect organic revenue growth between 4% and 5% and diluted non-GAAP earnings per share in the range of $5.40 and $5.50. We also raised our dividend to $0.70 per share quarterly and $2.80 per share annually. This is the 47^th consecutive year of dividend increases. Read our full financial results for more information.

L009-05222024

Related content

Five healthcare technology trends in 2024

Medtronic launching a new frontier in treating high blood pressure